Overview

Study of Pembrolizumab Maintenance Following First-Line Platinum Based Chemotherapy in Patients With Metastatic Squamous - Non-Small Cell Lung Cancer (sNSCLC)

Status:
Unknown status

Trial end date:
2021-05-01

Target enrollment:

Participant gender:

Summary

A Phase II Randomized, Double-Blind, Placebo-Controlled Study of Pembrolizumab Maintenance Following First-Line Platinum Based Chemotherapy in Patients with Metastatic Squamous - Non-Small Cell Lung Cancer (sNSCLC).

Phase:

Phase 2

Details

Lead Sponsor:

AIO-Studien-gGmbH

Collaborator:

Merck Sharp & Dohme Corp.

Treatments:

Pembrolizumab